Voclosporin

TRADE NAME: Lupkynis (Aurinia Pharmaceuticals)
INDICATIONS: Treatment of adult patients with active lupus nephritis (in combination with immunosuppressive therapy)
CLASS: Calcineurin inhibitor
HALF-LIFE: Approximately 30 hours

FDA APPROVAL DATE: 01/22/2021
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Clarithromycin, CYP3A4 inducers , CYP3A4 inhibitors, Diltiazem, Fluconazole, Itraconazole, Ketoconazole, P-gp substrates, Verapamil
PREGNANCY: May cause fetal harm. Advise patient not to breastfeed.

See adverse reactions attributed to class:
Calcineurin inhibitor

WARNING: MALIGNANCIES AND SERIOUS INFECTIONS

INCREASED RISK FOR DEVELOPING MALIGNANCIES AND SERIOUS INFECTIONS WITH VOCLOSPORIN OR OTHER IMMUNOSUPPRESSANTS THAT MAY LEAD TO HOSPITALIZATION OR DEATH

See full prescribing information for complete boxed warning

Please login to view the rest of this drug profile.

Page last updated 08/20/2025

Litt's app available free to subscribers

Search drug eruptions and reactions data anytime, anywhere

Incidence - Help

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness - Help

Hospitalization possible
Life threatening
Fatal

Warnings in other populations - Help

Breast feeding

Geriatric

Pediatric

Voclosporin comment watch save

Voclosporin